Clinical Trial Update: Omalizumab to Treat Eosinophilic Gastroenteritis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating omalizumab for eosinophilic gastroenteritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Gastroenteritis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gastroenteritis | Phase 2 | Status: COMPLETED